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Objective: While the prognostic factors of survival for patients with hepatocellu-
lar carcinoma (HCC) who underwent transarterial chemoembolization (TACE) are
well known, the clinical significance of performing selective TACE for HCC
patients has not been clearly documented. We tried to analyze the potential fac-
tors of disease-free survival for these patients, including the performance of
selective TACE.
Materials and Methods: A total of 151 patients with HCC who underwent
TACE were retrospectively analyzed for their disease-free survival (a median fol-
low-up of 23 months, range: 1-88 months). Univariate and multivariate analyses
were performed for 20 potential factors by using the Cox proportional hazard
model, including 19 baseline factors and one procedure-related factor (conven-
tional versus selective TACE). The parameters that proved to be significant on
the univariate analysis were subsequently tested with the multivariate model.
Results: Conventional or selective TACE was performed for 40 and 111
patients, respectively. Univariate and multivariate analyses revealed that tumor
multiplicity, venous tumor thrombosis and selective TACE were the only three
independent significant prognostic factors of disease-free survival (p = 0.002,
0.015 and 0.019, respectively). 
Conclusion: In our study, selective TACE was a favorable prognostic factor for
the disease-free survival of patients with HCC who underwent TACE. 
urgical resection or transplantation has been considered as the gold
standard for the treatment of hepatocellular carcinoma (HCC) in those
patients who are good surgical candidates (1, 2). However, the surgical
indications are usually very limited, and consequently transarterial chemoemboliza-
tion (TACE) has been widely practiced for the treatments of patients with unresectable
HCC (3-8). The additional survival benefit of TACE over conservative managements
has been analyzed in many previous randomized studies (8-14). Furthermore, the
potential prognostic factors affecting the survival of patients with HCC who undergo
TACE have been analyzed in many previous studies (15-18). Since the 1990’s
selective TACE such as segmental or subsegmental TACE has been performed to
achieve favorable clinical results with regards to local tumor progression and overall
survival (19-24). However, as far as we know, the survival benefit of selective TACE
compared to conventional TACE has not been clearly reported in the literature. 
In this study, we evaluated potential prognostic factors of disease-free survival for
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Spatients with HCC who underwent TACE, while we
focused on the role of selective TACE.
MATERIALS AND METHODS
Patients Selection
The requirements for patients to enter the study were as
follows: (a) adult patients with hepatic cirrhosis and HCC
(b) a prothrombin time ratio (i.e., the normal time divided
by the patient’s time) greater than 40%, (c) a platelet count
higher than 40,000 per cubic millimeter (40×10
9 /L), (d)
newly diagnosed patients with no previous treatment for
the HCC, (e) the patient was ineligible for surgical
resection or transplantation, (f) the patient agreed to
undergo TACE. 
From August 1, 1998 to July 15, 2006, a total of 151
consecutive patients with HCC who underwent TACE in
our hospital met the inclusion criteria, and the medical
records of the patients were retrospectively reviewed. All
of the 151 patients were monitored from the time of
diagnosis to the date of death or to the time of study
closure, if they were still alive. The study was censored on
July 15, 2007. All of the patients had a known 1-year or
longer survival status. The median follow-up period was 23
months (range: 1-88 months). All but seven patients were
male. Their age ranged from 44 to 82 years (mean ± SD
[standard deviation]: 64.2 ± 8.5 years). The other charac-
teristics are shown in Table 1. The Institutional Review
Board (IRB) of our hospital approved this study.  
The diagnosis of HCC was verified histologically by
performing a percutaneous needle biopsy for 12 patients
(7.9%). For the other patients, a diagnosis was established
based on the characteristic radiological features on at least
two imaging examinations. These examinations included
ultrasound, contrast-enhanced dynamic computed
tomography (CT), magnetic resonance imaging (MRI) and
hepatic angiography (for the hypervascular tumors seen on
two or more imaging modalities), or the use of a single
imaging technique with positive findings for HCC and an
associated serum α -fetoprotein level > 400 ng/mL (25). In
the majority of patients, the etiology of the cirrhosis was
chronic viral hepatitis B or hepatitis C (Table 1).
Chemoembolization Techniques 
All patients had enhanced dynamic CT performed within
four weeks prior to TACE. Informed consent was obtained
for all of the patients before the procedure. All the TACE
procedures were performed by two interventional radiolo-
gists with ten and six years of experience, respectively.
Hepatic angiography was performed using 5 Fr
angiographic catheters, followed by superselection of
arterial feeders using a microcatheter (mainly Progreat
TMα ;
Terumo; Tokyo, Japan). 
We administered an iodized oil-doxorubicin hydrochlo-
ride (Adriamycin; Kyowa Hakko Kogyo, Tokyo, Japan)
emulsion into the feeders. The volume of the iodized oil
ranged from 3 to 10 ml, and the amount of doxorubin
ranged from 20 to 70 mg. Once the flow became sluggish,
gelatin sponge particles (Gelfoam; Upjohn, Kalamazoo,
MI) that were mixed with mitomycin-C (Kyowa Hakko
Kogyo, Tokyo, Japan) and the contrast material were
additionally administered into the feeders. 
For selective TACE, chemoembolization was performed
selectively as possible in the distal arteries that fed the
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Table 1. Patient and Tumor Characteristics at Baseline
Characteristics No. %
Age  < 66 years 70 46.4%
≥66 years 81 53.6%
Underlying causes Hepatitis B 73 48.3%
Hepatitis C 44 29.1%
Hepatitis B and C 2 01.3%
Others 32 21.2%
Performance score 0 89 58.9%
1-2 62 41.1%
Platelet count (×10
9/L) ≥ 100,000 81 53.6%
< 100,000 70 46.4%
Portal hypertension No 84  55.6%
Yes 67 44.4%
Presence of ascites No 122 80.8%
Yes 29 19.2%
Child-Pugh class A 109 72.2%
B 39 25.8%
C3 02.0%
Serum α -fetoprotein level ≤ 50 ng/mL 75 49.7%
> 50 ng/mL 76 50.3%
Tumor number Single 77 51.0%
2-3 56 37.1%
≥4 18 11.9%
Tumor maximal diameter ≤3 cm 78 51.7%
3-5 cm 44 29.1%
> 5 cm 29 19.2%
Tumor distribution Unilobar 118 78.8%
Bilobar 33 21.6%
Portal or hepatic vein thrombosis  No 138 91.4%
Yes 13 08.6%
AJCC TNM staging I 69 45.7%
II 56 37.1%
III / IV 26 17.2%tumor (24). While performing selective TACE, attempts
were made to completely occlude the arterial feeders. A
small amount of saline solution was then injected slowly to
confirm the complete occlusion of the segmental or subseg-
mental arterial feeder. If the retained contrast media was
partially washed out after the saline injection, then
additional gelatin sponge particles were infused until
complete stasis of flow was achieved. 
Conventional TACE was defined as TACE at the level of
the right or left lobar hepatic artery or the proper hepatic
artery. When catheterization of a segmental tumor feeder
failed, then TACE was performed through the right or left
hepatic arteries. Conventional TACE was performed more
frequently when the tumors were supplied by multiple
segmental arterial feeders. 
For bilobar disease, we tried to treat all the tumors by
selective TACE, if possible. If the patient’s liver function
was as poor as Child-Pugh class B or C, then only the
larger tumors were selectively treated to preserve the liver
function. When performing conventional TACE, occlusion
of the arterial feeders was not intended, and only stasis of
flow was obtained at the end of the procedure. This was
done to minimize possible damage to the liver
parenchyma.
Imaging Interpretation and Follow-up
The CT examinations were performed with an 8-slice
multidetector CT scanner (Lightspeed; GE Medical
Systems, Milwaukee, WI) with 5-mm collimation and 17.5
mm/sec table speed, or with a single-detector helical
scanner (Prospeed Advantage; GE Medical Systems,
Milwaukee, WI) with 10-mm collimation and a 10-mm/sec
table speed. All the patients underwent both non-enhanced
and contrast-enhanced three-phase helical CT one-month
after their TACE. Two radiologists with twelve and seven
years of experience, respectively, interpreted the CT and
angiographic images independently, and the final decisions
were reached by consensus. 
A residual viable tumor was judged to be present when
an enhanced portion was seen within or around the
original tumor on a one-month follow-up CT scan. If no
definite evidence of residual tumor was noted on this one-
month follow-up CT, then 3-phase contrast-enhanced CT
was performed at a 3- or 4-month interval thereafter.
Local tumor progression was judged to be present when
eccentric focal disappearance of the iodized oil from the
lesion was seen, or an enhanced portion was seen within or
at the margin of the original mass on the next follow-up
CT scans after the first one-month follow-up CT scan (26,
27). Radiofrequency ablation was first considered for the
recurred small tumor that was ≤ 3 cm in the maximal
diameter, if the tumor was not located in a difficult
location. Additional TACE procedures were performed for
other tumors. Repeated procedures were based on the
tumor response and the patient’s tolerance, and were not
performed at a fixed time interval.
Analysis of the Prognostic Factors for Disease-Free
Survival and the Image Interpretation
Disease-free survival was calculated by considering any
death or recurrence as an event (28). All the patients were
followed up with a standard protocol of surveillance that
included performing a contrast-enhanced dynamic CT scan
at one month after TACE, followed by a liver function test,
a test for the serum α -fetoprotein level, a dynamic CT scan
and chest radiography every three months or when the
serum α -fetoprotein level was significantly increased (29).
When recurrence was indicated by any of these examina-
tions, the patients underwent hepatic angiography. 
The disease-free survival was the only end point of this
study, and this was analyzed for 20 potential prognostic
factors, including 14 baseline patient factors (the patient’s
age and gender, hepatitis B infection, hepatitis C infection,
the presence of ascites, the serum aspartate aminotrans-
ferase [AST] level, the serum alanine aminotransferase
[ALT] level, the serum albumin level, the total bilirubin
level, the platelet count, the prothrombin time [INR ratio],
the Child-Pugh class, the presence of portal hypertension
and the performance status score), five baseline tumor
factors (the serum α -fetoprotein level, the tumor location
that was either unilobar or bilobar, multiplicity of the
tumors, the maximal tumor diameter and portal or hepatic
vein tumor thrombosis), and finally one procedure-related
factor (conventional versus selective chemoembolization). 
Portal hypertension was defined by the presence of
either esophageal varices or splenomegaly with a platelet
count < 100,000/ml (30). The performance status assess-
ment followed the guidelines of the Eastern Cooperative
Oncology Group (ECOG) (31). The number of tumors was
determined from the pre-embolization CT. Tumor size was
determined as the maximal diameter of the nodule that
was measured on the pre-embolization CT. Vascular
invasion was assessed by dynamic CT and hepatic angiog-
raphy. Lymph node invasion and distant metastases were
assessed via a routine screening study such as ultrasonogra-
phy, dynamic CT and chest X-ray. Bone scintigraphy or a
brain CT was performed if suggestive symptoms were
present. Abdominal lymph nodes with the shortest
diameter being 10 mm or greater were regarded as
metastatic nodes. 
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For the 20 potential prognostic factors of disease-free
survival, univariate and multivariate analyses were
performed by using the Cox proportional hazard regres-
sion model, respectively. The main focus of analysis was
on the role of selective TACE. The parameters that proved
to be significant on the univariate analysis were
subsequently tested with the multivariate model. The
backward stepwise selection (likelihood ratio) technique
was used for the multivariate test. For the survival
analysis, multivariate analysis was performed twice, with
and without inclusion of the procedure-related factors. If
any independently significant baseline prognostic factor
was not dropped by the addition of a procedure-related
factor, then the confounding between the baseline and
procedure-related factors was regarded as insignificant.
The existence of variance inflation was also checked. For
continuous variables, the cut-off was set at the median
values on the univariate and multivariate analyses, while
giving consideration to the clinical context. 
P-values less than 0.05 were considered statistically
significant. The SPSS software package (version 10.0; SPSS
Inc., Chicago, IL) was used for the statistical analysis. 
RESULTS
Among the 20 potential prognostic factors affecting
disease-free survival, univariate analysis revealed that the
presence of ascites, a higher serum α -fetoprotein level (>
40 ng/mL), a bilobar tumor distribution, tumor multiplic-
ity, the tumor size and venous tumor thrombosis were the
only significant baseline prognostic factors (p = 0.046,
0.016, 0.006, 0.000, 0.022 and 0.001, respectively). In
addition, selective TACE was a significant procedure-
related factor on the univariate analysis (p = 0.000) (Table
2). 
Multivariate analysis for the prognostic factors that
affected disease-free survival on the univariate analysis
revealed that tumor multiplicity, venous tumor thrombosis
and selective chemoembolization were the only three
independently significant prognostic factors of disease-free
survival (p = 0.002, 0.015 and 0.019, respectively) (Table
3). The two independently significant baseline factors were
the same irrespective of including selective TACE in the
multivariate analysis, except for minute numerical changes.
The variance inflation was also minimal for the three
significant factors after the addition of selective TACE in
the multivariate analysis. 
Conventional or superelective TACE was performed in
40 and 111 patients, respectively. Superselective TACE
could not be performed because of the tumor extent (28
patients) or the vascular anatomy (12 patients). Among the
40 patients who underwent conventional TACE, the 1-, 2-,
3-, 4- and 5-year overall survival rates were 79%, 50%,
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Table 2. Univariate Analysis of Prognostic Factors Affecting Disease-Free Survival of Patients with Hepatocellular Carcinoma
who Underwent Transarterial Chemoembolization
Regression Coefficient Standard Error Odds Ratio (95% CI) P value
Age (< 66 vs. ≥ 66 years) 0.187 0.172 1.205 (0.860-1.690) 0.279
Gender (female/male) 0.176 0.457 1.192 (0.486-2.922) 0.701
Performance status score (0/1-2) 0.347 0.179 1.415 (0.996-2.010) 0.052
Hepatitis B infection (no/yes) 0.052 0.173 1.053 (0.751-1.477) 0.763
Hepatitis C infection (no/yes) -0.139 0.194 0.870 (0.596-1.271) 0.472
Serum AST level (≤40 vs. > 40 units/L) 0.223 0.178 1.250 (0.882-1.771) 0.210
Serum ALT level (≤40 vs. > 40 units/L) 0.076 0.173 1.079 (0.769-1.513) 0.661
Presence of ascites 0.373 0.187 1.453 (1.005-2.097) 0.046*
Serum albumin level (≥3.5 vs. < 3.5 g/dL) 0.325 0.178 1.384 (0.976-1.962) 0.068
Total bilirubin (≤1.0 vs. > 1.0 mg/dL) 0.063 0.174 1.065 (0.757-1.500) 0.717
Platelet count (≥100 vs. < 100 [×10
9/L]) -0.043 0.173 0.958 (0.682-1.344) 0.803
Portal hypertension (no/yes) 0.310 0.176 1.363 (0.966-1.925) 0.078
Prothrombin time ratio (INR ≤1.15 vs. > 1.15) -0.031 0.175 0.970 (0.688-1.366) 0.861
Child-Pugh class (A/B/C) 0.267 0.175 1.306 (0.926-1.842) 0.128
Serum α -fetoprotein level (≤40 vs. > 40 ng/mL)  0.421 0.174 1.523 (1.083-2.142) 0.016*
Tumor location (unilobar/bilobar) 0.574 0.209 1.775 (1.177-2.675) 0.006*
Tumor multiplicity (single/multiple) 0.686 0.179 1.985 (1.397-2.820) 0.000*
Tumor size (≤ 3 cm vs. > 3 cm)  0.398 0.174 1.488 (1.059-2.093) 0.022*
Venous tumor invasion (no/yes) 1.104 0.312 3.016 (1.637-5.555) 0.000*
Selective chemoembolization (no/yes) -0.698 0.197 0.498 (0.338-0.732) 0.000*
Note.─ * statistically significant (p value < 0.05), CI = confidence interval36%, 28% and 21%, respectively. The median survival
was 24 months. The number of TACE sessions ranged from
1 to 12 (average: 2.3 sessions). The 1-, 2- and 3-year
disease-free survival rates were 24%, 9% and 3%, respec-
tively. The 1-, 2- and 3-year disease-free survival rates for
patients who underwent selective TACE were 30%, 12%
and 4%, respectively (the median disease-free survival: 6
months). The 1-, 2- and 3-year disease-free survival rates
for patients who underwent conventional TACE were 8%,
3% and 0%, respectively (the median disease-free
survival: 2 months).
The initial one-month follow-up CT revealed complete
loss of contrast enhancement of the tumors in 98 patients
(65%). Local tumor progression occurred in 87 patients.
New foci of tumor occurred in 73 patients. For the residual
or recurred HCC tumors, we performed additional TACE
for 60 patients, local ablative therapies for six patients and
combined therapy of TACE and ablative therapies for 11
patients. Conservative management was done for the other
patients. At the end of the study, 110 patients had expired.
Among them, 72 patients died with recurrent HCC. There
was no procedure-related mortality.
DISCUSSION
The survival benefit of TACE over conservative manage-
ment has been analyzed in many previous randomized
studies and review articles (8-14). However, to the best of
our knowledge, there have been no randomized trials or
controlled studies for determining the survival benefit of
selective TACE over conventional TACE. While consider-
ing the additional cost and procedural time of segmental or
subsegmental TACE, it would be necessary to evaluate
whether selective TACE can induce an additional overall
or disease-free survival benefit so as to compensate for the
additional cost and time of performing this procedure. 
We think that improved disease-free survival status can
be expected by the potential merits of selective TACE as
follows: (1) damage to the liver parenchyma can be
restricted to the specific liver segments, and (2) the tumori-
cidal effect can be potentiated because the chemoembolic
agents are focused into specific liver segments (21, 22).
Despite these potential merits, it was not clear whether
selective TACE could enhance the disease-free survival
status of patients, when compared to conventional TACE.
The beneficial effect of initial selective TACE might have
been weakened by the high rate of intra-hepatic tumor
recurrence, especially for patients with viral hepatitis-
originated HCC (32). However, this study showed that
selective TACE could improve the disease-free survival
status of patients with inoperable HCC.
In this study, the significant baseline prognostic factors
for disease-free survival were similar to the factors for
tumor recurrence, as were determined by the previous
studies on TACE (19, 20, 22). Further more in our study,
the most powerful adverse prognostic factor of survival
was portal or hepatic venous thrombosis, and similar
results were found by previous studies on patients who
were treated with liver resection or transplantation (33-
35).
The limitations of this study are as follows. First, this was
a retrospective analysis and not a randomized controlled
trial. However, we did not perform a randomized
controlled study between selective and conventional
TACE because of the anticipated potential advantages of
selective TACE. Although we did not perform a controlled
study, the impact of selective TACE on patient survival
was adjusted by the multivariate analysis. Second, the
number of patients who underwent conventional TACE
was relatively small when compared to those patients who
underwent selective TACE. Third, the intrahepatic or
extrahepatic tumor recurrence might have been underesti-
mated. However, the main focus of this study was not to
evaluate the tumor recurrence rate itself, but to evaluate
the prognostic impact of procedure-related factors on the
disease-free survival. 
In conclusion, selective TACE could prolong the disease-
free survival period of patients with inoperable HCC, as
was shown by the multivariate analysis. A future larger
scale controlled study between conventional TACE and
selective TACE will be helpful to further evaluate this
subject. 
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Table 3. Independent Significant Prognostic Factors Affecting Disease-Free Survival as Determined by Multivariate Analysis
Multivariate Analysis for Disease-Free Survival
Regression Coefficient Standard Error Hazard Ratio (95% CI) P value
Multiplicity of tumor -0.567 0.183 1.764 (1.232-2.525) 0.002*
Portal or hepatic vein tumor thrombosis -0.779 0.320 2.179 (1.163-4.081) 0.015*
Selective chemoembolization -0.484 0.206 0.617 (0.412-0.923) 0.019*
Note.─ * statistically significant (p value < 0.05)Acknowledgement
The authors thank Park SH, MD, Department of
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